BIOSECURE Act and COINS Act updates-1

On 3 November, we hosted an expert session with a lawyer specializing in cross-border export regulations and compliance in a leading law firm in China. With a distinct focus on the BIOSECURE Act and related US investment restrictions, the expert covered the designation of biotechnology companies of concern (BCC), the implications for customer contracts, the potential legal remedies, and the outlook for US-China cooperation. The expert's overall assessment was that the policy framework is becoming clearer and the near-term impact should be manageable, supported by transition arrangements. Over the longer term, however, restrictions could weigh on cross-border collaboration. According to the expert, the Office of Management and Budget (OMB) is expected to issue the BCC list by 18 December 2026. Companies should receive 90 days advance notice and have an opportunity to challenge their proposed designation. The restrictions would primarily constrain new contracts involving US federal fundi